IL6 and neoplasm: Elevated IL-6 levels in patients with mCRPC predict malignant prostate cancer progression and poor outcomes in patients with localized tumors [123,124] Furthermore, we demonstrated that JunD inhibition results in GADD45α- and γ-dependent induction of cell death and inhibition of tumor growth [110].